RUBEN
NOGUEIRAS POZO
Investigador Oportunius
Universidad de Sevilla
Sevilla, EspañaPublicacións en colaboración con investigadores/as de Universidad de Sevilla (5)
2024
-
Correction to: Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial (Nature Communications, (2024), 15, 1, (5251), 10.1038/s41467-024-49121-3)
Nature Communications
-
Correction to: dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe (Nature Communications, (2024), 15, 1, (3736), 10.1038/s41467-024-47751-1)
Nature Communications
-
Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)
Gastroenterologia y Hepatologia
-
dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe
Nature Communications, Vol. 15, Núm. 1
2023
-
Neddylation of phosphoenolpyruvate carboxykinase 1 controls glucose metabolism
Cell Metabolism, Vol. 35, Núm. 9, pp. 1630-1645.e5